HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Proposes Liver, GI Risk Warnings For OTC Pain Relievers

This article was originally published in The Tan Sheet

Executive Summary

FDA proposes adding warnings on labeling for OTC pain relievers to advise consumers of "potential health risks" associated with acetaminophen and NSAIDs such as aspirin, ibuprofen and naproxen

You may also be interested in...

Proposed OTC Acetaminophen Warnings Not Supported By Science – McNeil

Existing science on the safety and efficacy of OTC acetaminophen does not substantiate several FDA-proposed warnings to be included in labeling for the analgesic, McNeil Consumer Healthcare asserts

FDA’s Labeling Changes For OTC Pain Relievers Need Flexibility – CHPA

FDA's proposed changes to warning flags displayed on the front of some OTC pain relief products "would benefit from greater flexibility," according to the Consumer Healthcare Products Association

Sen. Grassley Questions FDA’s Response To Acetaminophen Concerns

Sen. Chuck Grassley, R-Iowa, asks FDA to account for its lag time in reacting to acetaminophen safety concerns in a March 20 letter to Commissioner Andrew von Eschenbach

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts